Histone deacetylases (HDACs) are critical in the control of gene expression, and
dysregulation of their activity has been implicated in a broad range of diseases, including
cancer, cardiovascular, and neurological diseases. HDAC inhibitors (HDACi) employing
different zinc chelating functionalities such as hydroxamic acids and benzamides have
shown promising results in cancer therapy. Although it has also been suggested that HDACi
with increased isozyme selectivity and potency may broaden their clinical utility and …